BPC-157

Overview

BPC-157 is a synthetic peptide of 15 amino acids (a pentadecapeptide). Its sequence corresponds to a partial fragment of a larger protein, body protection compound (BPC), that was identified in human gastric juice. It is also referred to in the literature as PL 14736 or bepecin. The compound has been investigated in a substantial body of preclinical (mostly rodent) research for apparent effects on tissue repair, particularly in the musculoskeletal and gastrointestinal systems, as well as on blood-vessel formation (angiogenesis) and the gut–brain axis.

A key point of context: despite a large and growing volume of laboratory and animal publications, rigorous human clinical evidence is essentially absent. A 2025 systematic review of orthopaedic sports-medicine literature identified 36 included studies, of which only one involved human subjects: a small retrospective case series. The bulk of what is known about BPC-157 therefore describes what happens in rats and in cell culture, not in people.

Chemistry and structure

BPC-157 is a single linear chain of 15 amino acid residues with no disulfide bonds or cyclization.

The proline-rich stretch near the N-terminus (Pro-Pro-Pro) is frequently cited as contributing to the molecule's reported stability. Several authors describe it as relatively stable in human gastric juice for extended periods, which is sometimes offered as a rationale for oral administration in research settings. The proprietary salt forms studied or nominated for compounding include BPC-157 (free base) and BPC-157 acetate.

Mechanism of action

Proposed mechanisms come almost entirely from in vitro and animal experiments. No single, definitively established receptor for BPC-157 has been identified, and the mechanistic literature is dominated by a small number of research groups. The most frequently described pathways are:

• Angiogenesis via VEGFR2. In endothelial cell and rodent ischemia models, BPC-157 has been reported to increase VEGFR2 expression and to promote its internalization, activating the downstream VEGFR2–Akt–eNOS signaling axis. This was associated with increased vessel density in chick chorioallantoic membrane (CAM) and tube-formation assays and faster blood-flow recovery in the ischemic rat hind limb (Hsieh et al., 2017).
• Nitric oxide (NO) system modulation. Multiple papers describe interaction with NO pathways relevant to blood flow, vascular tone, and cytoprotection.
• Growth-factor, collagen, and fibroblast effects. In tendon explant and fibroblast studies, BPC-157 was reported to accelerate cell outgrowth, improve cell survival under oxidative (H2O2) stress, and increase fibroblast migration, effects linked to the FAK–paxillin pathway (Chang et al., 2011).
• Gut–brain axis and neuromodulation. Review work proposes that peripherally administered BPC-157 may influence dopaminergic, serotonergic, GABAergic, and opioid systems and exert downstream central effects, though this remains theoretical and animal-based (Sikiric et al., 2016).

Research and evidence

The evidence base is heavily weighted toward animal and in vitro studies. Where human data exist, they are small, preliminary, or unpublished. The table and subsections below label evidence type explicitly.

Musculoskeletal (tendon, ligament, muscle): animal evidence

This is the most-studied area. In a rat Achilles-detachment model, BPC-157 was reported to promote tendon-to-bone healing and to counter corticosteroid-induced impairment, with improvements in functional, biomechanical, and histological measures (Krivic et al., 2006). In vitro work on tendon explants and fibroblasts described accelerated outgrowth, better survival under oxidative stress, and increased cell migration (Chang et al., 2011). These findings are animal- and cell-based; they have not been replicated in adequately powered human trials.

Gastrointestinal protection: animal evidence

BPC-157 originates from gastric-juice research, and a large share of the literature examines GI applications: protection against NSAID-induced lesions, healing of gastric and intestinal injury, and effects in models of inflammatory bowel conditions (Sikiric et al., 2011). Again, these are predominantly rodent studies; the peptide's developmental history includes an earlier compound, PL 14736, explored for inflammatory bowel disease.

Angiogenesis and cytoprotection: animal and in vitro evidence

The pro-angiogenic and cytoprotective effects described above (VEGFR2–Akt–eNOS, NO-system modulation) are supported by cell-culture and rodent ischemia experiments (Hsieh et al., 2017). The same pro-angiogenic activity is also the basis of a theoretical safety concern about tumor angiogenesis (see Safety).

Neurological and gut–brain axis — early/theoretical

Reviews propose neuroprotective and behavioral effects (anxiolytic, anticonvulsant, antidepressant-like) and roles in nerve regeneration and traumatic injury models, framed through gut–brain signaling (Sikiric et al., 2016). This work is animal-based and largely from one research network; human relevance is unestablished. Readers interested in peptides studied for cognitive or neural endpoints may compare entries such as Semax, Selank, DSIP, and Cerebrolysin, which have their own distinct (and similarly limited) evidence profiles.

Human evidence: sparse and inconclusive

Human data are minimal. Keep these exposures distinct:

• A retrospective case series of 12 patients receiving intra-articular injection for chronic knee pain reported relief in some individuals (described in Vasireddi et al., 2025). This is uncontrolled and low-quality evidence.
• NCT02637284 — registered Phase I oral safety/pharmacokinetics study of a BPC-157-containing product (PCO-02 / "bepecin") in healthy volunteers. Results were never posted or published; status is effectively unknown/cancelled in later commentary. This is the unpublished formal Phase I registration most often meant when sources say "the Phase I never reported."
• Earlier PL 14736 / Veljaca-era exploration (including an enema Phase I abstract in older GI literature) is a separate historical thread from NCT02637284 and must not be collapsed into that registry ID.
• Lee & Burgess 2025 intravenous pilot (n=2) is a tiny uncontrolled exposure — not a formal Phase I program and not a substitute for NCT02637284.
• NCT07437547 — Phase 2 randomized, placebo-controlled trial for acute hamstring strain (Hudson Biotech), subcutaneous BPC-157 with rehabilitation, recruiting as of 2026 listings; no results posted. Supported as an ongoing trial record, not as efficacy evidence.

Clinical and regulatory status

BPC-157 has not received marketing approval from any major regulator. Its development history includes earlier clinical exploration under the designation PL 14736 for gastrointestinal indications, and a small number of registered trials (above), but no approved product has resulted.

U.S. FDA — compounding / bulk drug substances (timeline).

1. 2023 — Category 2 (historical). FDA placed BPC-157 into Category 2 of its interim 503A bulk-substance policy: substances associated with significant safety concerns (commonly framed as immunogenicity, peptide-related impurities, and limited human safety data) while evaluation continued. That listing was a real safety-risk signal for compounding — it was not a finding that human efficacy had been disproven in RCTs.
2. ~2026-04-22 — nomination withdrawn / off the active Category 2 table. FDA materials moved BPC-157 into the cohort of substances whose nominations were withdrawn, removing it from the active Category 2 table while retaining the documented risk narrative. Withdrawn ≠ cleared for compounding and ≠ placement on the final 503A bulks list (21 CFR 216.23).
3. 2026-07-23/24 — PCAC. BPC-157 (free base and acetate; ulcerative-colitis use context in briefing materials) was on the Pharmacy Compounding Advisory Committee agenda. Secondary reports describe a committee recommendation regarding compounding eligibility; a PCAC recommendation is not FDA approval to compound, not final rulemaking, and not drug approval. Exact vote tallies are not hard-coded here until locked to FDA primary minutes/transcript.

Safety and reported effects

Documented safety information is limited and comes mostly from animal toxicology and small/uncontrolled human exposure:

• Animal and review literature generally report few adverse effects at the doses studied, and some authors describe an absence of demonstrated toxicity in their models. This is not equivalent to established human safety.
• Long-term human safety is unknown. There are no large controlled human trials, no robust pharmacovigilance data, and the one registered Phase I human safety study never published results.
• A recurring theoretical concern is that a pro-angiogenic agent could, in principle, support the blood supply of tumors; this has not been demonstrated clinically but is raised in the literature as a reason for caution. The 2025 Pharmaceuticals exchange (Sikiric et al. comment vs Józwiak et al. review/reply) makes the dispute explicit: originators argue context-dependent/anti-tumor readings, while the reply states that published in-vivo tumor-growth/metastasis inhibition is lacking and that pro-angiogenic VEGFR2 signaling remains a plausible hazard — see Community claims.
• Because BPC-157 is sold largely as an unregulated research material, product quality, identity, and purity are not guaranteed, which is itself a safety concern independent of the molecule's intrinsic properties.

Doses used in published research

For factual completeness only, and not as guidance: published animal studies have administered BPC-157 across a wide range of doses (commonly expressed per kilogram of body weight in rodents) and by various routes, including intraperitoneal, intramuscular, and oral/in-drinking-water administration. The registered human Phase I study used oral administration of a tablet product, and the ongoing hamstring trial uses subcutaneous injection daily for 14 days. These statements name routes and trial duration only — they are not a human dose, reconstitution schedule, or self-administration protocol. dosing.established remains false. This entry does not provide milligram amounts for human use, administration instructions, or sourcing information.

Legal status

• United States. Not an approved drug. Not a lawfully marketed dietary supplement (peptides of this type do not meet the dietary-ingredient definition). Subject to the FDA compounding/bulk-substance actions described above. Commonly sold labeled "for research use only, not for human consumption."
• Sport. BPC-157 is named on the WADA 2026 Prohibited List under S0 (non-approved substances). It is not permitted for athletes subject to the WADA Code at any time. Site legality badges that mark this slug as WADA prohibited match that named list entry; treat the Prohibited List (and current WADA guidance) as controlling over any older “S0 catch-all only / not named” summaries.
• Norway. National medicines/customs enforcement has specifically targeted BPC-157 (customs stop-list addition reported for 2025 in this site's legality notes); import and sale of bioactive peptides intended for human use are treated as unapproved medicines. Rules can change — verify with current DMP/customs guidance.
• Other jurisdictions. It is generally not approved as a medicine elsewhere; national rules on possession, import, and sale of unapproved peptides vary. Country tiles on this site mark many EU states as "legal" in the narrow sense of not specifically scheduled, which is not the same as approved for human use.

This entry is educational and does not constitute legal or medical advice.

How it compares

BPC-157 sits alongside other peptides studied for tissue repair on this site, and the honest comparison is that none has robust human-trial evidence:

• TB-500, frequently used in the same injury-recovery context and often paired with BPC-157, but it is likewise supported almost entirely by animal data, with no human clinical trials of the marketed fragment.
• KPV, a small anti-inflammatory α-MSH fragment with a different (NF-κB-related) mechanism; also preclinical.

All three are research chemicals, none is approved for human use, and the strength of evidence is broadly similar (animal and in-vitro). See also the Recovery & injury overview for the wider picture.

Common misconceptions

• "BPC-157 is a natural substance found in the body." Its sequence is derived from a fragment of a gastric-juice protein, but the synthetic pentadecapeptide marketed as BPC-157 is a manufactured research compound, not a substance the body produces as such.
• "It's clinically proven to heal tendons and injuries." The supportive evidence is overwhelmingly from rats and cell culture. There is no completed, published human RCT showing efficacy for any indication.
• "It's FDA-approved (or a legal supplement)." It is neither. It is not an approved drug and does not qualify as a dietary supplement. FDA historically listed it under interim Category 2 safety concerns (2023); the nomination was later withdrawn (~2026-04-22) and PCAC discussed it in July 2026 — none of that equals marketing approval or final 503A bulks listing.
• "Animal safety data means it's safe for people." Favorable rodent toxicology does not establish human safety, and long-term human data do not exist.
• "BPC-157 and TB-500 are the same / interchangeable." They are distinct peptides with different sequences and mechanisms; claims pairing them are marketing conventions, not established science.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against the primary sources we could reach. A knowledgeable content creator is not peer review, so every statement below was treated as a claim to verify. Where we could trace a claim to a real primary source, we report it; where we could not, we say so plainly and note the gap rather than repeat the claim as established. A caveat worth stating up front: not locating a citation here does not make a claim false. A large amount of relevant work is not indexed in the databases we searched — paywalled journals, regional (including Russian and Chinese) literature, clinical and conference material, and unpublished or proprietary data — so absence of a traceable source is a limit of our reach, not a verdict on the underlying claim.

Additions with a traceable source

• Cardiac injury (animal). [Animal] In a rat isoprenaline-induced myocardial-infarction model, BPC-157 reduced necrosis markers (CK, CK-MB, LDH, troponin T), preserved left-ventricular systolic function, and normalized ECG changes (Barisic et al., Biomedicines 2022). This is a chemically induced injury in rats — not coronary-ligation infarction and not human data.
• Cerebral ischemia (animal). [Animal] In a rat hippocampal ischemia–reperfusion model (bilateral carotid clamping), a single application of BPC-157 (10 µg/kg) at reperfusion counteracted neural damage and produced full recovery on behavioral tests (water maze, beam-walk) at 24–72 h (Vukojević et al., Brain and Behavior 2020). The study reported functional recovery, not a quantified infarct-volume reduction.
• Cancer cachexia, not anti-tumor (animal). [Animal] In mice bearing C26 colon tumors, BPC-157 reduced muscle wasting, lowered IL-6 and TNF-α, and prolonged survival — but the tumors kept growing; it did not shrink tumor burden (Kang et al., Current Pharmaceutical Design 2018). This supports a role against cachexia symptoms, not against cancer itself.

Claims we could not trace to a source

• "BPC-157 reverses established cancers — a 65% tumor-burden reduction in colon tumors (Oncology Reports 2017)." We could not trace this specific study or figure to any identifiable published paper in the sources we searched. The one tumor-bearing in-vivo study we did locate (Kang et al., 2018) explicitly did not reduce tumor volume — the tumors grew. We found no controlled study, in the accessible literature, testing whether BPC-157 promotes or reverses tumors — which is a gap in what we can reach, not a finding either way. [not traceable in accessible sources]
• "Nature studies show BPC-157 enhances p53 and quadruples CD8+ T-cell infiltration, killing melanoma, colon, and breast cancer." We could not map these specific Nature citations to any locatable BPC-157 paper. The only direct cancer-cell work we found is a 2004 in-vitro conference abstract reporting melanoma growth inhibition via VEGF/MAPK (Radeljak et al., Melanoma Research 2004), which we did not find replicated in vivo. [In vitro, single abstract] Separately, and pointing the other way, BPC-157's pro-angiogenic, VEGFR2-upregulating activity is the basis of the opposite concern — a theoretical worry that it could feed a tumor's blood supply (see Safety) — so an anticancer effect should not be treated as established. [claim not traceable]
• "BPC-157 has selective angiogenesis — growing healthy vessels but shrinking tumor blood supply — cuts metastasis 80%, and reverses the Warburg effect to kill melanoma, colon, and breast cells (2016 Nature)." This is the subject of an open, unresolved scientific dispute — not a settled anti-cancer effect. The "context-dependent/selective angiogenesis" and "anti-tumor potential" argument originates with the compound's own discovering laboratory in a narrative review (Sikiric et al., Pharmaceuticals 2025), not from primary in-vivo tumor data. In the same 2025 journal exchange, independent reviewers reply directly that "no published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis," that the single 2004 melanoma cell-line result is unreplicated and "insufficient to support anticancer claims," and that BPC-157's documented pro-angiogenic signaling (VEGFR2–Akt–eNOS; Hsieh et al., J Mol Med 2017) "remains a plausible tumor-promoting hazard" (Józwiak et al., Reply, Pharmaceuticals 2025). We could not locate the "2016 Nature Warburg-reversal," "80% metastasis reduction," or "tumor-angiogenesis suppression" studies in any accessible source. The honest bottom line: the replicated direction of BPC-157's effect on blood vessels is pro-angiogenic; its originators hypothesise a tumor-selective exception that is unproven in vivo and actively contested; and the common TB-500 pairing is itself pro-angiogenic and pro-metastatic in several tumor models. Neither "cures cancer" nor "causes cancer" is established, and the documented mechanism weighs toward caution, not reassurance. [scientific dispute; specific figures not traceable]
• "It reverses heart attacks and regenerates dead heart tissue (World Journal of Cardiology 2018, 64% smaller infarct)." The cardiac evidence we could trace is the rat isoprenaline model above (Barisic et al., 2022) — biomarker and functional protection in animals, not regeneration of infarcted myocardium in people. We could not locate the cited journal, year, or percentage in the sources we searched. [Animal; cited figure not traceable]
• "Reduces stroke infarct volume by 50% (Journal of Cerebral Blood Flow and Metabolism 2008)." The rodent stroke work we could trace (Vukojević et al., 2020) reported behavioral recovery and did not measure a 50% infarct reduction; we could not locate the cited 2008 paper or statistic in the accessible literature. [cited statistic not traceable]
• "BPC-157 is naturally produced by your body — it's endogenous, safer than clean water, with zero adverse events in 30 years." The 15-amino-acid peptide is not reported to occur naturally in its intact form; its sequence was derived from a larger gastric-juice protein, but the fragment sold as BPC-157 is synthetic (see Common misconceptions). "Zero adverse events" reflects the absence of controlled long-term human safety data in what we could find — not positive evidence of safety. [overstated]

Frequently asked questions

Is BPC-157 actually dangerous, or is that a myth?

Neither claim has been established. Because there is no completed, published human safety trial, BPC-157 has not been shown to be dangerous — but it has equally not been shown to be safe [Animal data only]. Rodent toxicology has reported few adverse effects at the doses studied [Animal]. FDA's 2023 Category 2 placement documented unresolved concerns about immunogenicity, peptide impurities, and limited human safety data; after the ~2026-04-22 nomination withdrawal and July 2026 PCAC discussion, those safety themes remain part of the public record even though BPC-157 is no longer on the active Category 2 table and is still not on the final 503A bulks list. Separately, because most material is sold as an unregulated research chemical, contamination and mislabeling are real risks independent of the molecule itself.

Can you take BPC-157 indefinitely as a "forever" longevity peptide?

No study in any species has tested BPC-157 for lifespan extension or for open-ended long-term use, so the "forever peptide" framing is a marketing idea rather than a finding [Hypothesis]. Documented human exposures include the unpublished oral Phase I registration NCT02637284, a separate tiny IV pilot (Lee 2025, n=2), and the ongoing hamstring RCT NCT07437547 (protocol duration 14 days of study drug in listings) — none establishes long-term safety. This entry does not provide dosing or duration protocols.

Is BPC-157 being suppressed by the FDA or the pharmaceutical industry?

The straightforward reason BPC-157 has no approved product is that no sponsor has completed and published a human efficacy or safety trial — not that a proven cure is being hidden. FDA's Category 2 history, April 2026 nomination withdrawal, and July 2026 PCAC agenda are public regulatory steps, and human trials are registered (NCT02637284 unpublished; NCT07437547 ongoing) — the opposite of a blackout. Regulators approve drugs on completed trial data; the absence of that data, not a conspiracy, is what keeps BPC-157 unapproved. PCAC recommendation ≠ final 503A listing.

Does BPC-157 really "do everything" — heal the heart, kidneys, brain, diabetes, and depression?

Claims that one peptide reverses heart attacks, kidney disease, paralysis, diabetes, and depression trace almost entirely to rodent and cell-culture experiments, many from a single research network, and several widely repeated citations do not resolve to any real paper [Animal / In vitro]. A compound said to "do everything" across unrelated organ systems is a warning sign, not a credential: no completed human trial has demonstrated efficacy for any of these conditions. Consistent animal results are a reason to run human trials, not a substitute for them.

Does BPC-157 have to be injected, or does the oral form work?

Some animal studies used oral or in-drinking-water administration, and the one registered human Phase I study used an oral tablet — but none of these established efficacy in people by any route [Animal]. Blanket claims that "oral doesn't work" (or that it definitely does) go beyond the evidence: absorption and clinical effect in humans have not been demonstrated for oral, subcutaneous, or any other route. This entry does not recommend a route or method of use.